Skip To Main Content
Ondrej Havranek on Muck Rack

Ondrej Havranek

As seen in: Nature, MDPI, EY, Lexology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ondrej

Contact Ondrej, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas

|
By Eva Pokorna, Dmitry Manakov, Magdalena Klanova, Ondrej Havranek, Marek Trneny, Kristyna Nozickova, Petra Kovarikova, Alexandra Dolnikova, Nicol Renesova, Liliana Tuskova, Zuzana Vreckova, Pavel Klener
| Nature Verified
Abstract We evaluated the in vivo efficacy of polatuzumab vedotin (POLA), administered as a single agent or in combination with venetoclax (VEN), in relapsed/refractory (R/R) mantle cell lymphoma (MCL) and BCL2-positive diffuse large B-cell lymphoma (DLBCL). In addition, we investigated the mechanisms underlying acquired resistance to POLA in vivo.
Open in Who Shared Issue with article?

Inhibition of autoantigen-induced B-cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL) - Cell Death & Disease

|
By Patryk Górniak, Anna Polak, Kristýna Kupcová, Zofia Pilch, Dominika Nowis, R. Eric Davis, Ondrej Havranek, Anna Rams, Eliza Głodkowska-Mrówka, Przemysław Juszczyński
| Nature Verified
Abstract BCR signal dependency is a hallmark of diffuse large B-cell lymphoma (DLBCL) and other B-cell lymphoid malignancies originating from germinal centers. Chronic-active BCR signaling, typical for the more aggressive activated B-cell subtype (ABC) of DLBCLs, is often attributed to activating mutations within the BCR signaling cascade and continuous stimulation of the BCR by autoantigens.
Open in Who Shared Issue with article?

Current understanding of eryptosis: mechanisms, physiological functions, role in disease, pharmacological applications, and nomenclature recommendations | Cell Death & Disease

|
By Anton Tkachenko, Alessandro Attanzio, Michael Föller, Ondrej Havranek, Etheresia Pretorius, Ignazio Restivo
| Nature Verified
Abstract Early studies have shown that erythrocytes have caspase-3 and caspase-8 and are capable of dying through an apoptotic-like cell death triggered by Ca2+ ionophores. This cell death is associated with apoptosis-like morphological signs, including cell shrinkage, membrane blebbing, and phosphatidylserine externalization.
Open in Who Shared Issue with article?
See all 9 articles